Connect your AI

Beam Therapeutics BEAM Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

BridgeBio PharmaBBIO

——

IncyteINCY

——

Other financials

Income statement

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

Market cap$3.42B+24.5%

Profitability

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Beam Therapeutics's proceeds from issuance of common stock relating to employee stock plans?: Beam Therapeutics (BEAM) reported proceeds from issuance of common stock relating to employee stock plans of $1.51M in Q1 2026.
How has Beam Therapeutics's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Beam Therapeutics's proceeds from issuance of common stock relating to employee stock plans increased by 0.6% year-over-year, from $1.5M to $1.51M.